BP102

Phase 2Small molecule

Shanghai Hengrui Pharmaceutical Co., Ltd.

BP102 is one of 103 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerNot yet recruiting

Colorectal CancerNot yet recruiting

Malignant Solid TumorsRecruiting

SHR2554Not yet recruiting

Metastatic Colorectal CancerPhase 2

Not yet recruiting

Colorectal CancerPhase 2

Not yet recruiting

Malignant Solid TumorsPhase 2

Recruiting

SHR2554Phase 2

Not yet recruiting

Competition

Competitive Landscape

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 3

39 2

Camptosar

Pfizer

Phase 3

34 3

Keytruda

Merck & Co.

Phase 3

25 4

Fudr

Pfizer

Phase 3

17 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

8 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

4 7

5-Fu

TToray Industries, Inc

Phase 3

4 8

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 9

Calcium Levofolinate

FFujian Cancer Hospital

Phase 3

1 10

BP102

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

SHR2554

NCT06679673

Q1 2027

Phase 2Not yet recruiting

Metastatic Colorectal Cancer

NCT07061210

Q4 2028

Phase 2Recruiting

Malignant Solid Tumors

NCT07268040

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03645876·12 enrolled

An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07061210·20 enrolled

Non-squamous NSCLC1 trial

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03666728·5 enrolled

Malignant Solid Tumors1 trial

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT07268040·400 enrolled

SHR25541 trial

SHR-1701 Combined with SHR2554 and BP102 for MCRC

Not yet recruiting·FFudan University·Phase 2·NCT06679673·20 enrolled

Colorectal Cancer1 trial

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

Not yet recruiting·WWest China Hospital·Phase 1/2·NCT06373133·36 enrolled

1 more indication

Recurrent Glioblastoma1 trial

A Pilot Study of Chimeric Antigen Receptor (CAR) T Cells Targeting B7-H3 Antigen in Treating Patients With Recurrent and Refractory Glioblastoma

Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT04385173·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BP102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BP102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BP102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Hengrui Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Shanghai Hengrui Pharmaceutical Co., Ltd.

BP102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2028

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

Non-squamous NSCLC1 trial

Malignant Solid Tumors1 trial

SHR25541 trial

Colorectal Cancer1 trial

Recurrent Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News